GEMINI-1 and -2: Rates of Confirmed Virologic Withdrawal at Wk 96 Similar With DTG Plus 3TC vs DTG Plus FTC/TDF in Treatment-Naive Patients

March 8-11, 2020; Boston, Massachusetts
Detailed analysis of confirmed virologic withdrawals shows low risk of treatment-emergent resistance in treatment-naive patients treated with DTG/3TC for initial ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 163 KB
Released: March 13, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Expert-authored CCO slides on strategies encompassed by the Ending the HIV Epidemic Initiative, including prevention and rapid diagnosis and treatment

W. David Hardy, MD
Program Director
David A. Wohl, MD
Released: October 20, 2020

Expert-authored CCO slides on simplification to 2-drug ART, ART safety during pregnancy, ART and weight gain, and long-acting injectable ART

W. David Hardy, MD
Program Director
Michelle S. Cespedes, MD, MS
Released: October 20, 2020

CCO slides on ending the HIV epidemic in the United States via expanded testing, enhanced linkage to care, and rapid response to potential outbreaks

Lisa K. Fitzpatrick, MD, MPH, MPA David Malebranche, MD, MPH Released: October 7, 2020

Multimedia module from Clinical Care Options: HIV experts weigh in on selecting first-line ART and modifying ART for those with virologic suppression

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD W. David Hardy, MD Babafemi Taiwo, MBBS
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 18, 2020 Expired: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue